CompoAtlas

Northern cycle support

Originaltext auf Französisch.

In Kanada zugelassenes natürliches Gesundheitsprodukt

Falls dieses Produkt in Frankreich verkauft würde

Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.

Zusammensetzung

Arzneilicher Inhaltsstoff und QuelleJe Dosiseinheit laut QuelleTäglich höchstens, Erwachsene
L-carnitine

Quelle : L-tartrate de carnitine

100 milligrammeNicht berechnet
Vaccinium macrocarpon

Quelle : Fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 100 milligramme

10 milligrammeNicht berechnet
1,2-Diacylglycéro-3-phosphocholine

Quelle : Huile de soja

2,45 milligrammeNicht berechnet
Iode

Quelle : Iodure de potassium

4,2 microgrammesNicht berechnet
Ginkgo biloba

Quelle : Feuille

Extrakt : Matériel brut sec

Extraktionsverhältnis : 30:1

Trockenpflanzenäquivalent : 450 milligramme

15 milligrammeNicht berechnet
Hypericum perforatum

Quelle : Sommité

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 60 milligramme

6 milligrammeNicht berechnet
3-hydroxyméthylindole

Quelle : Indole-3-carbinol

20 milligrammeNicht berechnet
Lepidium meyenii

Quelle : Racine

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 200 milligramme

20 milligrammeNicht berechnet
Magnésium

Quelle : Oxyde de magnésium

3,5 milligramme35.000 µg
Manganèse

Quelle : Aspartate de manganèse (II)

0,4 milligramme4.000 µg
N-acétyl-l-cystéine

Quelle : N-Acétyl-L-cystéine

10 milligrammeNicht berechnet
Niacine

Quelle : Niacinamide

1 milligrammeNicht berechnet
Acide pantothénique

Quelle : D-Pantothénate de calcium

0,52 milligramme5.200 µg
1-[(2E, 4E)-5-(1,3-Benzodioxole-5-yl)-1-oxo-2,4-pentadiényl] pipéridine

Quelle : Piper nigrum - fruit

0,5 milligrammeNicht berechnet
Sélénium

Quelle : Sélénométhionine

3,5 microgrammesNicht berechnet
Silybum marianum

Quelle : Graine(s)

Extrakt : Matériel brut sec

Extraktionsverhältnis : 30:1

Trockenpflanzenäquivalent : 300 milligramme

10 milligrammeNicht berechnet
Taraxacum officinale

Quelle : Feuille

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 120 milligramme

12 milligrammeNicht berechnet
Tribulus terrestris

Quelle : Fruit

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 300 milligramme

30 milligrammeNicht berechnet
Choline

Quelle : Bitartrate de choline

4 microgrammesNicht berechnet
Urtica dioica

Quelle : Racine

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 30 milligramme

3 milligrammeNicht berechnet
Vitamine A

Quelle : Acétate de vitamine A

54,6 mcg EARNicht berechnet
Vitamine B12

Quelle : Cyanocobalamine

0,6 microgrammesNicht berechnet
Vitamine B6

Quelle : Chlorhydrate de pyridoxine

0,2 milligramme2.000 µg
Vitamine C

Quelle : Acide ascorbique

2 milligramme20.000 µg
Vitamine D

Quelle : Cholécalciférol

0,001 milligramme10 µg
Vitamine E

Quelle : Succinate d'acide de d-alpha tocophéryle

0,2 mg ATNicht berechnet
Vitamin K2

Quelle : Vitamin K2

0,006 milligramme60 µg
Withania somnifera

Quelle : Racine

Extrakt : Matériel brut sec

Extraktionsverhältnis : 10:1

Trockenpflanzenäquivalent : 200 milligramme

20 milligrammeNicht berechnet
L-Glutathione

Quelle : Glutathione

10 milligrammeNicht berechnet
Zinc

Quelle : Gluconate de zinc

2,5 milligramme25.000 µg
Acide 2-[[(3-alpha,5-bêta,7-bêta)-3,7-dihydroxy-24-oxocholan-24-yl]amino]éthanesulfonique

Quelle : Acide tauroursodésoxycholique

100 milligrammeNicht berechnet
Camellia sinensis

Quelle : Feuille

Extrakt : Matériel brut sec

Extraktionsverhältnis : 8:1

Trockenpflanzenäquivalent : 160 milligramme

Stärke : 10 milligramme Caffeine

20 milligrammeNicht berechnet
Acide 2-aminoéthanesulfonique

Quelle : Taurine

10 milligrammeNicht berechnet

Nicht arzneiliche Inhaltsstoffe

Hydroxypropyl méthylcellulose

In Kanada empfohlene Dosen

BevölkerungsgruppeAlterMenge pro EinnahmeHäufigkeit
AdultesNon précisée5 Capsule2 Tous les jours

In Kanada zugelassene Verwendungen

Hepatoprotectant/ liver protectant. Help(s) to support liver function. Source of antioxidants for the maintenance of good health. Used in Herbal Medicine to help reduce elevated blood lipid levels/ hyperlipidaemia in adults. Used in Herbal Medicine to help maintain cardiovascular health in adults. Helps to enhance cognitive function in adults. Helps to enhance memory in adults. Helps to support peripheral circulation. Used in Herbal Medicine to help reduce difficulty in urination associated with the early stages of benign prostatic hyperplasia (BPH) . Traditionally used in Herbal Medicine to increase the amount of urine to achieve flushing of the urinary tract as an adjuvant in minor urinary complaints. Helps to support/promote healthy estrogen metabolism/balance. Helps to support healthy mood balance during menopause. Used in Herbal Medicine to help relieve the pain associated with menstruation. Used in Herbal Medicine to help ease nervous tension (calmative). Used in Herbal Medicine to help relieve premenstrual symptoms. help(s) relieve symptoms associated with menopause. Used in Herbal Medicine to help relieve muscle and joint pain associated with rheumatic conditions (such as rheumatoid arthritis, osteoarthritis and/or fibrositis), and of pain associated with neuralgia (such as sciatica). Helps in the maintenance of bones. Helps to maintain immune function. Helps in connective tissue formation. Helps to maintain healthy skin. Helps to maintain the body's ability to metabolize nutrients. Helps in collagen formation. Aids in the muscle recovery process by reducing muscle tissue damage associated with a resistance training regimen. Helps support muscle tissue repair in individuals involved in resistance training. Source of Vitamins and minerals.

Originaltext auf Englisch.

Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.

Warnhinweise in Kanada

Contra-Indications : If you are taking antibiotics, do not use this product. If you are taking nitroglycerin, do not use this product. Do not use if you are taking health products that affect blood coagulation (e.g. blood thinners, clotting factor replacements, acetylsalicylic acid, ibuprofen, fish oils, vitamin E) as this may increase the risk of spontaneous bleeding. If you are pregnant or breastfeeding, do not use this product. Do not use if you are taking anti-cancer medications, blood thinners, antidepressant medications (e.g. selective serotonin reuptake inhibitors (SSRI)), anti-HIV agents, cardiovascular medications, immunosuppressants, and/or contraceptive medications.

Originaltext auf Englisch.

Cautions and Warnings : Consult a health care practitioner if symptoms persist or worsen. If you have a liver disorder, do not use. Consult a health care practitioner prior to use if you have an iron deficiency. If you have kidney stones, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you have diabetes or seizures. Consult a health care practitioner prior to use if you are taking cardiac glycosides such as digitalis/digoxin, or blood pressure medication. If you have gall bladder diseases, and/or intestinal obstruction, consult a health care practitioner prior to use. If you are taking medications or natural health products, consult a health care practitioner prior to use. If you are attempting to conceive, consult a health care practitioner prior to use. If you have symptoms of low estrogen (such as joint pain, mood changes, changes in libido, hot flashes, night sweats, vaginal dryness or irregular menstruations), consult a health care practitioner prior to use. If you develop liver-related symptoms (e.g. yellowing of the eyes and/or skin, dark urine, abdominal pain, jaundice) or symptoms of low estrogen, discontinue use and consult a health care practitioner. Avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy. Consult a health care practitioner prior to use if you are taking anti-anxiety medications, seizure medications, antihistamines, bronchodilators, muscle relaxants and/or opiates. Consult a health care practitioner prior to use if you are following a low protein diet. Consult a health care practitioner prior to use if you have a stomach ulcers or excess stomach acid. If you have heart disease, high or low blood pressure, kidney disorder, diabetes or edema (Swelling of hands, face and feet) or are taking products containing diuretics, do not use. Stop use and seek medical attention immediately if you experience dizziness, confusion, muscle weakness or pain, abnormal heart beat and/or difficulty breathing. Consult a health care practitioner prior to use if you are taking protease inhibitors. To exclude the diagnosis of a serious cause of hormonal imbalance, consult a health care practitioner prior to use. Consumption with alcohol, other drugs or natural health products with sedative properties is not recommended.

Originaltext auf Englisch.

Known Adverse Reactions : Hypersensitivity, such as allergy, has been known to occur; in which case, discontinue use. Some people may experience mild gastrointestinal disturbances, nausea, restlessness and/or headaches.

Originaltext auf Englisch.

Produktdaten

Andere Namen
Northern Shield
Inhaber
Northern Sports Nutrition
NPN oder DIN-HM
80076732
Status
Aktive Lizenz
Lizenzdatum
13. April 2017
Überarbeitungsdatum
30. Dezember 2020
Form
Capsule
Verabreichungsweg
Orale
Art des Antrags
Non traditionnelle

Quelle

Amtlicher Health-Canada-Eintrag, Zulassung 80076732

Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Originaltext auf Englisch.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Originaltext auf Französisch.

Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.

Offizielle Warnhinweise (Health Canada)

Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:

  • L-carnitine
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    L-CARNITINE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (CPS 2008).

    Von Health Canada zitierte Quellen (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a seizure disorder (CPS 2008).

    Von Health Canada zitierte Quellen (1)
    • CPS 2008: Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Monografie von Health Canada vom 25. Juli 2025

  • Vaccinium macrocarpon
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    CRANBERRY - VACCINIUM MACROCARPON

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Von Health Canada zitierte Quellen (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomisierte Studie
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Von Health Canada zitierte Quellen (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Fallbericht
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Anwendungsbedingung: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. März 2026

    DRIED CRANBERRY JUICE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).

    Von Health Canada zitierte Quellen (2)
    • Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomisierte Studie
    • Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).

    Von Health Canada zitierte Quellen (4)
    • Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Fallbericht
    • Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.

    Anwendungsbedingung: (Recurrent) urinary tract infection.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografie von Health Canada vom 27. März 2026

  • Ginkgo biloba
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    GINKGO - GINKGO BILOBA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Von Health Canada zitierte Quellen (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Von Health Canada zitierte Quellen (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Gegenanzeigen

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Von Health Canada zitierte Quellen (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Von Health Canada zitierte Quellen (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematische Übersicht
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Monografie von Health Canada vom 25. Juli 2025

  • Hypericum perforatum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ST. JOHN'S WORT -HYPERICUM PERFORATUM- Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: Healthy mood balance.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005).

    Von Health Canada zitierte Quellen (3)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
    • Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking seizure medications, antihistamines, bronchodilators, muscle relaxants and/or opiates (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; Kawaguchi et al. 2004; Morimoto et al. 2004; Eich-Höchli et al. 2003; Dresser et al. 2003; Hoffman 2003; Markowitz et al. 2003; Xie et al. 2003; Dannawi 2002; Gurley et al. 2002; Spinella and Eaton 2002; Wang et al. 2002; Parker et al. 2001; Wang et al. 2001; Burstein et al. 2000; Nebel et al. 1999).

    Von Health Canada zitierte Quellen (17)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
    • Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. 2000. Lack of effect of St John's Wort on carbazepine pharmacokinetics in healthy volunteers. Clinical Pharmacology and Therapeutics 68(6):605-612.
    • Dannawi M. 2002. Possible serotonin syndrome after combination of buspirone and St John's wort. Journal of Psychopharmacology 16(4):401.
    • Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73(1):41-50.
    • Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. 2003. Methadone maintenance treatment and St John's wort: a case report. Pharmacopsychiatry 36(1):35-37.
    • Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. 2002. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical Pharmacology and Therapeutics 72(3):276-287.
    • Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. 2004. Drug interaction between St John's Wort and quazepam. British Journal of Clinical Pharmacology 58(4):403-410.
    • Markowitz JS, Donovan JL, DeVane CL, Talor RM, Ruan Y, Wang J, Chavin KD. 2003. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. The Journal of the American Medical Association. 290(11):1500-1504.
    • Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
    • Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. 2004. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. Journal of Clinical Pharmacology 44(1):95-101.
    • Nebel A, Schneider BJ, Baker RK, Kroll DJ. 1999. Potential metabolic interaction between St. John's wort and theophylline. The Annals of Pharmacotherapy 33(4):502.
    • Parker V, Wong AH, Boon HS, Seeman MV. 2001. Adverse reactions to St John's wort. Canadian Journal of Psychiatry 46(1):77-79.
    • Spinella M, Eaton LA. 2002. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Injury 16(4):359-367.
    • Wang ZQ, Hamman MA, Huang SM, Lesko LJ, Hall SD. 2002. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clinical Pharmacology and Therapeutics 71(6):414-420.
    • Wang ZQ, Gorski C, Hamman MA, Huang S, Lesko LJ, Hall SD. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70(4):317-326.
    • Xie R, Tan L, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ. 2003. CYP3A and P-glycoprotein induction with St. John's wort in healthy volunteers of selected ethnic populations. Journal of Clinical Pharmacology 45(3):352-356.

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    When using this product avoid prolonged exposure to sunlight, ultraviolet light (UV) or UV therapy (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; ESCOP 2003; Hoffmann 2003; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (6)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Hoffmann D. 2003. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. 1997. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press.
    • Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Bilia et al. 2002; Ernst et al. 1998).

    Von Health Canada zitierte Quellen (2)
    • Bilia AR, Gallori S, Vincieri FF. St John's wort and depression: efficacy, safety and tolerability - an update. Life Sciences 2002;70(26):3077-3096. PubMed Übersichtsartikel
    • Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). European Journal of Clinical Pharmacology 1998;54:589-594. PubMed Systematische Übersicht

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Gegenanzeigen

    Do not use if you are taking antidepressants, anxiolytics, anti-cancer, cardiovascular, contraceptive medications, blood thinners, anti-HIV agents and/or medications to suppress the immune system (Brinker 2010; Barnes et al. 2007; Bradley 2006; Mills and Bone 2005; Murphy et al. 2005; Frye et al. 2004; Hebert et al. 2004; Jiang et al. 2004; Mueller et al. 2004; Smith et al. 2004; Sparreboom et al. 2004; Tannergren et al. 2004; Wichtl 2004; Alscher and Klotz 2003; Bauer et al. 2003; Dresser et al. 2003; ESCOP 2003; Hall et al. 2003; Hoffmann 2003; Pfrunder et al. 2003; Schwarz et al. 2003; Bolley 2002; Gorski et al. 2002; Mathijssen et al. 2002; Ahmed et al. 2001; De Maat et al. 2001; Moschella and Jaber 2001; Roby et al. 2001; Sugimoto et al. 2001; Turton-Weeks 2001; Wang et al. 2001; Barone et al. 2000; Durr et al. 2000; Karliova et al. 2000; Mai et al. 2000; Piscitelli et al. 2000; Ruschitzka et al. 2000; Ernst 1999; Johne et al. 1999; Maurer et al. 1999; Rey and Walter 1998).

    Von Health Canada zitierte Quellen (41)
    • Ahmed SM, Banner NR, Dubrey SW. 2001. Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients. Journal of Heart and Lung Transplantation 20(7):795.
    • Alscher DM, Klotz U. 2003. Drug interaction of herbal tea containing St. John's wort with cyclosporine. Transplant International 16(7):543-544.
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. 2000. Drug interaction between St. John's wort and cyclosporine. The Annals of Pharmacotherapy 34(9):1013-1016.
    • Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer HH, Roots I, Mai I. 2003. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. British Journal of Clinical Pharmacology 55(2):203-211.
    • Bolley R, Zülke C, Kammerl M, Fischereder M, Krämer BK. 2002. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 73(6):1009.
    • Bradley PR, editor. 2006. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications. 2010.
    • De Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. 2001. Drug interaction between St John's wort and nevirapine. AIDS 15(3):420-421.
    • Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics 73(1):41-50.
    • Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. 2000.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Ernst E. 1999. Second thoughts about the safety of St. John's wort. Lancet 354(9195):20142016.
    • Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. 2004. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology and Therapeutics 76(4):323-329.
    • Gorski JC, Hamman MA, Wang Z, Vasavada N, Huang S, Hall SD. 2002. The effect of St John's wort on the efficacy of oral contraception. Clinical Pharmacology and Therapeutics 71:P25.
    • Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. 2003. The interaction between St. John's wort and an oral contraceptive. Clinical Pharmacology and Therapeutics 74(6):525-535.
    • Hebert MF, Park JM, Chen YL, Akhatar S, Larson AM. 2004. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 44(1):89-94.
    • Hoffmann D. 2003. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press.
    • Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. 2004. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology 57(5):592-599.
    • Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich, M, Roots I. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clinical Pharmacology and Therapeutics 66(4):338-345.
    • Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE. 2000. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. Journal of Hepatology 33(5):853-855.
    • Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer HH, Roots I. 2000. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. International Journal of Clinical Pharmacology and Therapeutics 38(10):500-502.
    • Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. 2002. Effects of St John's wort on irinotecan metabolism. Journal of the National Cancer Institute 94(16):1247-1249.
    • Maurer A, Johne A, Bauer S, Brockmoller F, Conath I, Roots M, Langheinrich M, Hubner WD. 1999. Interaction of St. John's wort extract with phenprocoumon [Abstract]. European Journal of Clinical Pharmacology 55:A22.
    • Mills S, Bone K. 2005. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone.
    • Moschella C, Jaber BL. 2001. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. American Journal of Kidney Diseases 38(5):1105-1107.
    • Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. 2004. Effect of St. John's wort dose and preparations on the pharmacokinetics of digoxin. Clinical Pharmacology and Therpeutics 75(6):546-557.
    • Murphy A, Kern SE, Stanczyk FZ, Westhoff CL. 2005. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 71(6):402-408.
    • Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. 2003. Interaction of St. John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. British Journal of Clinical Pharmacology 56(6):683-690.
    • Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. 2000. Indinavir concentrations and St John's wort. Lancet 355(9203):547-548.
    • Rey JM, Walter G. 1998. Hypericum perforatum (St John's wort) in depression: pest or blessing? The Medical Journal of Australia 169(11-12):583-586.
    • Roby CA, Dryer DA, Burstein AH. 2001. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. Journal of Clinical Psychopharmacology 21(5):530-532.
    • Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. 2000. Acute heart transplant rejection due to Saint John's wort. Lancet 355(9203):548-549.
    • Schwarz UI, Büschel B, Kirch W. 2003. Unwanted pregnancy on self- medication with St John's wort despite hormonal contraception. British Journal of Clinical Pharmacology 55(1):112-113.
    • Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. 2004. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 24(11):1508-1514.
    • Sparreboom A, Cox MC, Acharya MR, Figg WD. 2004. Herbal remedies in the United States: potential adverse interactions with anticancer agents. Journal of Clinical Oncology 22(12):2489-2503.
    • Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. 2001. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clinical Pharmacology and Therapeutics 70(6):518-524.
    • Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. 2004. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clinical Pharmacology and Therapeutics 75(4):298-309.
    • Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. 2001. St John's wort: a hidden risk for transplant patients. Progress in Transplantation 11(2):116-120.
    • Wang ZQ, Gorski C, Hamman MA, Huang S, Lesko LJ, Hall SD. 2001. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clinical Pharmacology and Therapeutics 70(4):317-326.
    • Wichtl M, editor. 2004. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis, 3rd edition. Stuttgart (D): Medpharm GmbH Scientific Publishers.

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Bekannte Nebenwirkungen

    When using this product you may experience mild gastrointestinal disturbances, restlessness, and/or headaches (Barnes et al. 2007; ESCOP 2003).

    Von Health Canada zitierte Quellen (2)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience muscle rigidity or contractions, tremors, agitation/confusion, increased heart rate, or hypersensitivity/allergy (Boyer 2023; Mayo Clinic Staff 2022; Erner et al. 2003; Papakostas et al. 2007; Barnes et al. 2007; ESCOP 2003).

    Von Health Canada zitierte Quellen (6)
    • Barnes J, Anderson LA, Philipson JD. 2007. Herbal Medicines, 3rd edition. London (GB): The Pharmaceutical Press.
    • Boyer EW. Liebelt EL, Ganetsky M. 2023. Serotonin syndrome (serotonin toxicity). UpToDate. [Accessed 2023 September 11]. Available from: https://www.uptodate.com/contents/serotonin-syndrome-serotonin-toxicity
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme.
    • Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. 2003. Serotonin Syndrome and Other Serotonergic Disorders, Pain Medicine, Volume 4, Issue 1, Pages 63-74.
    • Mayo Clinic Staff. 2022. Persistent depressive disorder. Mayo Clinic. [Accessed 2023 September 11]. Available from : https://www.mayoclinic.org/diseases-conditions/persistent-depressive-disorder/diagnosis-treatment/drc-20350935
    • Papakostas GI, Crawford CM, Scalia MJ, Fava M. 2007. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology 56(2-3):132-137.

    1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).

    Monografie von Health Canada vom 26. Juli 2024

    ST. JOHN'S WORT - HYPERICUM PERFORATUM - Topical

    Vorsichtsmaßnahmen und Warnhinweise

    For external use only.

    When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.

    Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.

    Gegenanzeigen

    Do not use on deep or puncture wounds, animal bites or serious burns.

    Monografie von Health Canada vom 28. Februar 2025

  • Lepidium meyenii
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    Maca - Lepidium Meyenii

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Gilt für Produkte: providing 0.6 g or more dried root/hypocotyl, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).

    Von Health Canada zitierte Quellen (1)
    • Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Randomisierte Studie

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Von Health Canada zitierte Quellen (2)
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomisierte Studie
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Anwendungsbedingung: Healthy mood balance; Sexual health.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Von Health Canada zitierte Quellen (3)
    • Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Übersichtsartikel
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomisierte Studie
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Monografie von Health Canada vom 27. September 2024

  • Silybum marianum
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    MILK THISTLE - SILYBUM MARIANUM

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Brinker 2010; Mills et al. 2006).

    Von Health Canada zitierte Quellen (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills E, Dugoua J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation : An Evidence-Based Approach. London (UK): Taylor and Francis Medical; 2006.

    Bekannte Nebenwirkungen

    Stop use if hypersensitivity/allergy occurs (Geier et al. 1990; Mironets et al. 1990).

    Von Health Canada zitierte Quellen (2)
    • Geier J, Fuchs Th, Wahl R. [Anaphylactic shock due to an extract of Silybum marianum in a patient with immediate-type allergy to Kiwi fruit]. Anaphylaktischer Schock durch einen Mariendistel-Extrakt bei Soforttyp-Allergie auf Kiwi. Allergologie 1990;13(10):387-388 (in German).
    • Mironets VI, Krasovskaia EA, Polischuk II. [A case of urticaria during carsil treatment]. Vrachebnoe Delo 1990;(7):86-87 (in Russian).

    Monografie von Health Canada vom 26. Juni 2026

  • Tribulus terrestris
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    TRIBULUS - TRIBULUS TERRESTRIS

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products except Vrsya (aphrodisiac for men).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Chen and Chen 2004).

    Von Health Canada zitierte Quellen (1)
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Anwendungsbedingung: Traditional Chinese Medicine.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have qi or blood deficiency (Bensky et al. 2004).

    Von Health Canada zitierte Quellen (1)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.

    Gegenanzeigen

    Anwendungsbedingung: Traditional Chinese Medicine.

    Do not use if you have low blood pressure or liver deficiency (Bensky et al. 2004; Chen and Chen 2004).

    Von Health Canada zitierte Quellen (2)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use if hypersensitivity/allergy occurs (Bensky et al. 2004)

    Von Health Canada zitierte Quellen (1)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.

    Anwendungsbedingung: All products except Mutrala (diuretic).

    When using this product diuretic effect may occur.

    Monografie von Health Canada vom 29. Mai 2026

  • Urtica dioica
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    STINGING NETTLE JUICE

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products except nutritive tonics.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Gegenanzeigen

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).

    Von Health Canada zitierte Quellen (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products except those making only a diuretic claim*.

    When using this product diuretic effect may occur.

    *Note: This statement can be removed from the label if a diuretic claim is included.

    Monografie von Health Canada vom 27. März 2026

    STINGING NETTLE - URTICA DIOICA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products except nutritive tonics.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Gegenanzeigen

    Do not use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Tilgner 1999).

    Von Health Canada zitierte Quellen (3)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Tilgner S. Herbal Medicine from the Heart of the Earth. Creswell (OR): Wise Acre Press; 1999.

    Bekannte Nebenwirkungen

    All products except those making only a diuretic claim*

    When using this product diuretic effect may occur.

    *Note: This statement can be removed from the label if a diuretic claim is included.

    Monografie von Health Canada vom 27. März 2026

  • Vitamine D
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    VITAMIN D (>1,000 - 2,500 IU)

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Von Health Canada zitierte Quellen (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Gilt für Produkte: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Gilt für Produkte: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Gegenanzeigen

    Anwendungsbedingung: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Gilt für Produkte: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Bekannte Nebenwirkungen

    Anwendungsbedingung: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Von Health Canada zitierte Quellen (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Gilt für Produkte: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Von Health Canada zitierte Quellen (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografie von Health Canada vom 26. Juni 2026

  • Withania somnifera
    Warnhinweis, Geltungsbedingung und zitierte Studien lesen

    Offizieller Originaltext auf Englisch.

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Art der Anwendung: Oral

    Vorsichtsmaßnahmen und Warnhinweise

    Anwendungsbedingung: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Anwendungsbedingung: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Von Health Canada zitierte Quellen (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Von Health Canada zitierte Quellen (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Monografie von Health Canada vom 28. Februar 2025

Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.

Liste in der amtlichen Überarbeitung vom (Register: Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise).

Verpackung fotografieren

Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.

Liste aus dem Jahr 2020. Fotografieren Sie die Verpackung, um Änderungen zu prüfen.

Eingabetaste zum Analysieren, Umschalt+Eingabetaste für eine neue Zeile